Exact Sciences (EXAS) Guides Q4 Revenue of $551-$553M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
January 8, 2023 3:45 PM ESTPreliminary fourth quarter highlights:
Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $401.8-$402.8 million and Precision Oncology revenue of $142.9-$143.9 millionExpected total 2022 revenue, excluding COVID-19 testing, increased 25% compared to 2021, with Screening revenue of $1,423.0-$1,424.0 million and Precision Oncology revenue of $601.0-$602.0 millionAdjusted EBITDA profitability now expected for the fourth quarter 2022 and full year 2023, ahead of previous target of third quarter 2023MADISON, Wis., Jan. 8, 2023... More
